Core Insights - Esperion has announced the acquisition of Corstasis Therapeutics, which developed Enbumyst, the first FDA-approved nasal spray diuretic for edema associated with congestive heart failure, hepatic, and renal diseases [1][2][4] Transaction Details - The acquisition involves an upfront cash payment of $75 million, with potential additional payments of up to $180 million based on regulatory and commercial milestones, along with low double-digit royalties on Enbumyst sales [9][10] - The transaction is expected to close in the second quarter of 2026, subject to customary closing conditions [11] Product Overview - Enbumyst is a self-administered outpatient diuretic therapy that addresses the needs of patients with edema related to congestive heart failure, liver disease, and kidney disease [3][13] - The product targets a U.S. market opportunity exceeding $4 billion, with potential expansion into hepatic and renal indications [5][6] Strategic Rationale - The acquisition aligns with Esperion's Vision 2040, which aims to deliver innovative cardiovascular solutions to high-need patient populations [6] - Enbumyst complements Esperion's existing cardiovascular commercial infrastructure and enhances its portfolio in metabolic, hepatic, and renal diseases [6][4] Clinical Significance - The availability of Enbumyst is expected to improve patient management by providing a rapid and flexible treatment option for fluid management at home, potentially reducing hospitalizations [8][4]